Hologic, Inc. (HOLX) Return on Equity (ROE): 10.37%
Is Hologic, Inc.’s return on equity (ROE) high or low?
Hologic, Inc.'s return on equity (ROE) of 10.37% is 58% below its 5-year average of 24.66%, near the low end of its 5-year range (9.09%–44.36%).
The return on equity (ROE) for Hologic, Inc. (HOLX) is 10.37% as of Wednesday, June 10, 2026. It is below its 12-month average by 22.03% (13.30%).
HOLX Return on Equity (ROE) Chart
HOLX Average Return on Equity (ROE) Chart
HOLX Current vs Average Return on Equity (ROE) Chart
HOLX Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
10.37%
RETURN ON EQUITY (ROE) AVG TTM
13.30%
RETURN ON EQUITY (ROE) AVG 3Y
15.60%
RETURN ON EQUITY (ROE) AVG 5Y
24.66%
RETURN ON EQUITY (ROE) AVG 10Y
17.32%
RETURN ON EQUITY (ROE) AVG 15Y
8.22%
RETURN ON EQUITY (ROE) AVG 20Y
3.13%
CURRENT VS TTM AVG
-22.03%
CURRENT VS 3Y AVG
-33.51%
CURRENT VS 5Y AVG
-57.95%
CURRENT VS 10Y AVG
-40.13%
CURRENT VS 15Y AVG
+26.18%
CURRENT VS 20Y AVG
+230.91%
HOLX Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | — | 10.37% | 13.30% | 15.60% | 24.66% |
| Moderna, Inc. (MRNA) | $18.94B | -32.62% | -32.64% | -13.90% | 0.25% |
| Align Technology, Inc. (ALGN) | $12.76B | 10.13% | 10.54% | 10.84% | 19.93% |
| BioNTech SE (BNTX) | $21.87B | -5.68% | -4.55% | 10.63% | 21.70% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Waters Corporation (WAT) | $24.19B | 25.09% | 29.98% | 64.02% | 111.55% |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | -4.56% | -2.13% | 6.32% | 9.65% |
| Bio-Rad Laboratories, Inc. (BIO) | $8.03B | 10.20% | -8.94% | -15.72% | 1.14% |
| Veeva Systems Inc. (VEEV) | $27.37B | 12.60% | 12.42% | 12.32% | 13.45% |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 23.73% | 25.09% | 5.57% | 0.40% |
Return Analysis
ROE
10.4%
ROA
5.9%
Hologic, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Hologic, Inc. (HOLX)?
- The return on equity (ROE) for HOLX stock is 10.37%.
- Is Hologic, Inc.'s return on equity (ROE) high or low?
- Hologic, Inc.'s return on equity (ROE) of 10.37% is 58% below its 5-year average of 24.66%, near the low end of its 5-year range (9.09%–44.36%).
- What is the TTM average return on equity (ROE) for Hologic, Inc. (HOLX)?
- The TTM average return on equity (ROE) for HOLX stock is 13.30%.
- What is the 3Y average return on equity (ROE) for Hologic, Inc. (HOLX)?
- The 3Y average return on equity (ROE) for HOLX stock is 15.60%.
- What is the 5Y average return on equity (ROE) for Hologic, Inc. (HOLX)?
- The 5Y average return on equity (ROE) for HOLX stock is 24.66%.
- What is the 10Y average return on equity (ROE) for Hologic, Inc. (HOLX)?
- The 10Y average return on equity (ROE) for HOLX stock is 17.32%.
- What is the 15Y average return on equity (ROE) for Hologic, Inc. (HOLX)?
- The 15Y average return on equity (ROE) for HOLX stock is 8.22%.
- What is the 20Y average return on equity (ROE) for Hologic, Inc. (HOLX)?
- The 20Y average return on equity (ROE) for HOLX stock is 3.13%.
Hologic, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-27 | 11.21% |
| 2024-09-30 | 15.39% |
| 2023-09-30 | 9.09% |
| 2022-09-30 | 26.70% |
| 2021-09-30 | 44.36% |
| 2020-09-30 | 41.22% |
| 2019-09-30 | -1.76% |
| 2018-09-30 | -4.58% |
| 2017-09-30 | 27.13% |
| 2016-09-30 | 15.44% |
| 2015-09-30 | 6.33% |
| 2014-09-30 | 0.84% |
| 2013-09-30 | -60.41% |
| 2012-09-30 | -2.49% |
| 2011-09-30 | 5.35% |
| 2010-09-30 | -2.33% |
| 2009-09-30 | -86.61% |
| 2008-09-30 | -8.31% |
| 2007-09-30 | 11.74% |
| 2006-09-30 | 4.53% |
| 2005-09-30 | 12.97% |
| 2004-09-30 | 7.32% |
| 2003-09-30 | 1.94% |
| 2002-09-30 | 0.13% |
| 2001-09-30 | -18.65% |
| 2000-09-30 | -14.15% |
| 1999-09-30 | -2.46% |
| 1998-09-30 | 7.41% |
| 1997-09-30 | 13.96% |
| 1996-09-30 | 10.62% |
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini